Verastem, Inc. VSTM
8.60 USD +0.19 (+2.26%)
Nov 9, 2026, 10:21 AM EST
8.18 Day range 8.69
3.43 52-week range 10.82
- YTD
- +11.40%
- 1 year
- +6.57%
News
marketbeat.com What Verastem (VSTM) Said on Its Q3 Earnings Call Verastem NASDAQ: VSTM reported $24 million in third-quarter 2026 net product revenue as refills of its ovarian cancer treatment offset a moderation in new patient starts. The company also outlined…
benzinga.com RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $18 RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $19 to $18.
benzinga.com HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $20 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $18 to $20.
benzinga.com Verastem Oncology Q3 2026 Earnings Call Transcript Verastem Oncology (NASDAQ:VSTM) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Verastem Oncology Files $100M At-The-Market Equity Offering Agreement With Cantor Fitzgerald This registration statement contains the following documents:• a base prospectus, which covers the offering, issuance and sale by us of an indeterminate amount of the securities identified below from…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.
benzinga.com Verastem Q3 Adj. EPS $(0.72) Misses $(0.46) Estimate, Sales $24.012M Miss $26.078M Estimate Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.46) by 56.52 percent. This is a 33.33 percent decrease over losses of $(0.54)…
businesswire.com Verastem Oncology to Participate in Upcoming November Investor Conferences BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its…- benzinga.com Mizuho Maintains Outperform on Verastem, Raises Price Target to $14 Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and raises the price target from $13 to $14.
benzinga.com Jefferies Maintains Buy on Verastem, Raises Price Target to $13 Jefferies analyst Faisal Khurshid maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $11 to $13.
benzinga.com RBC Capital Maintains Outperform on Verastem, Raises Price Target to $19 RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and raises the price target from $14 to $19.- benzinga.com Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.
benzinga.com BTIG Maintains Buy on Verastem, Raises Price Target to $24 BTIG analyst Jeet Mukherjee maintains Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $18 to $24.
benzinga.com Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers Verastem Oncology reports promising VS-7375 response rates in pancreatic, colorectal, and lung cancers, with a Phase 3 trial planned for 2026.
benzinga.com Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.- benzinga.com Verastem Oncology Appoints Michael P. Bailey As President And CEO, Effective January 1, 2027 Mr. Bailey will also continue to serve on the Company’s Board of Directors. The CEO transition follows the planned retirement of Daniel Paterson, who will step down as President and CEO and continue…
benzinga.com Verastem Oncology Announces Initial Data In First Multi-Tumor Update From Ongoing TARGET-D 101 Phase 1/2 Clinical Trial Evaluating VS-7375; Data Demonstrate Robust Clinical Activity With Favorable Safety And Tolerability Profile Across Multiple Dose Levels And Tumor Types VS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L; responses are durable with a…- benzinga.com Verastem Oncology Q2 2026 Earnings Call Transcript Verastem Oncology (NASDAQ:VSTM) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…
benzinga.com BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.
benzinga.com HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.- benzinga.com Verastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026 RAMP 201 molecular profiling showed clinically meaningful activity in KRAS wild-type recurrent LGSOC, including ORRs of 22% in patients with NRAS- or BRAF-mutated tumors and 18% in patients with…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
benzinga.com Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ETVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with…- benzinga.com Mizuho Maintains Outperform on Verastem, Lowers Price Target to $13 Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $14 to $13.
- benzinga.com Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12 Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $14 to $12.
- benzinga.com Verastem Q2 Adj. EPS $(0.35) Beats $(0.43) Estimate, Sales $25.078M Beat $23.093M Estimate Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.43) by 18.6 percent. This is a 44.44 percent increase over losses of $(0.63) per…
- benzinga.com Verastem Oncology Doses First Participant In Its TARGET-D 203 Phase 2 Study Of VS-7375 To Treat Metastatic Colorectal Cancer Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Tenet Healthcare (NYSE:THC) shares rose 14.1% to $227.06 during Thursday's after-market session. The company's market cap stands at $17.1 billion. As per the news, the Q2 earnings report came…- benzinga.com Verastem Oncology Doses First Patient In Phase 2 Trial Of VS-7375 For KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer And Untreated Asymptomatic Untreated Brain Metastases TARGET-D 202 (NCT07659782) is a global, open-label, Phase 2 registration-directed trial evaluating VS-7375 monotherapy at the recommended Phase 2 dose (RP2D) of 900 mg daily (QD) in patients with…
benzinga.com These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.- benzinga.com RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14 RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $15 to $14.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
- benzinga.com Verastem Oncology Data From TARGET-D 101 Phase 1/2 Clinical Study Of VS-7375 Shows Encouraging Clinical Activity Including Favorable Safety Profile; Broad Anti-Tumor Activity Observed Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive preliminary data from the…
benzinga.com Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer Verastem updated RAMP 205 data showed 86% six-month survival in metastatic pancreatic cancer and continued tumor shrinkage.- benzinga.com Verastem Announces Updated Safety, Efficacy Results From RAMP 205 Evaluating Avutometinib Plus Defactinib In Combination With Gemcitabine And Nab-Paclitaxel In First-Line Metastatic Pancreatic Cancer 90% of patients in the study presented with metastatic (Stage IV) disease at diagnosis6-month overall survival rate was 86%; follow-up continues and survival data continue to matureVerastem Oncology…
- benzinga.com Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of VS-7375 To KRAS G12D-Mutated Metastatic Pancreatic Ductal Carcinoma Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been…
- benzinga.com Verastem Oncology To Report Progress Across VS-7375 Oral KRAS G12D (ON/OFF) TARGET-D Clinical Program And Updated Preliminary Data From Phase 1/2 TARGET-D 101 Dose Escalation And Dose Expansion Trial Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trialCompany to host investor conference call and webcast on Tuesday, June 23, 2026, at 4:30 pm ET
- benzinga.com Verastem Obtains U.S. FDA Fast Track Designation For VS-7375; Phase 1 TARGET-D 101 Dose Escalation, Dose Expansion, And Combination Clinical Trial Ongoing With Early Data Updates Expected In The First Half Of 2026 And More Mature Data Expected In The Second Half Of 2026 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug…
- benzinga.com Mizuho Maintains Outperform on Verastem, Lowers Price Target to $14 Mizuho analyst Graig Suvannavejh maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $16 to $14.
benzinga.com Earnings Scheduled For March 4, 2026 
benzinga.com Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday 
benzinga.com Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket